EFFICIENCY OF XENOGENEIC ANTITUMOR VACCINE IN VIVO
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-24-1-2022-g.10377Keywords:
cancer vaccine, cytotoxic activity, Ehrlich carcinoma, Lewis lung carcinoma, tumor growth inhibitionAbstract
Means of immunotherapy including cancer vaccines are believed to improve the outcome of cancer patients’ treatment. In the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology a new cancer vaccine based on extracts of embryonic xenogeneic proteins combined with microbially-derived adjuvants is under investigation. Aim: to study the anticancer efficacy and some immunological effects of the newly constructed xenogeneic cancer vaccine (XAV) in mice bearing Lewis lung carcinoma or Ehrlich carcinoma (EC). Materials and methods: the study was carried out on Balb/c and C57Bl mice transplanted ether with EC or Lewis lung carcinoma (LLC) respectively. Immunization with the XAV started shortly after the tumor cells transplantation (EC and LLC models) or after the primary tumor was surgically removed (LLC model). Anticancer and antimetastatic effects of the XAV were studied. Cytotoxic activity of lymphocytes, macrophages and blood serum was determined in MTT-assay. Results: immunization with XAV inhibited the growth of primary tumor in both experimental models, reduced metastatization in mice bearing LLC and significantly prolonged survival time of mice bearing EC. At the terminal stages of tumor growth, cytotoxic activity of lymphocytes and macrophages in vaccinated animals was elevated comparing with unvaccinated animals independently of experimental tumor. Conclusion: the newly designed xenogeneic cancer vaccine demonstrated promising anticancer efficacy and deserve further investigation.
References
Moingeon P. Cancer vaccines. Vaccine 2001; 19 (11–12): 1305–26. doi: 10.1016/s0264–410x(00)00372–8
Naftzger C, Takechi Y, Kohda H, et al. Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 1996; 93 (25): 14809–14. doi: 10.1073/pnas.93.25.14809
Wang M, Xie Z, Shi M, et al. A new strategy to induce effective antitumor response in vitro and in vivo. Scand J Immunol 2008; 68 (3): 287–96. doi: 10.1111/j.1365–3083.2008.02140.x
Erenprace YG. Embryonic properties of tumor cells: facts and hypotheses. Exp Oncol 1982; 4 (6): 13–8.
Sioud M, Sоrensen D. Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. Eur J Immunol 2003; 33 (1): 38–45. doi: 10.1002/immu.200390005
Potebnya GP, Symchych TV, Lisovenko GS. Xenogenic cancer vaccines. Exp Oncol 2010; 32 (2): 61–5.
Su J-M, Wei Y-Q, Tian L, et al. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 2003; 63 (3): 600–7.
Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med 2007; 232 (9): 1130–41. doi: 10.3181/0702-MR-42
Kuzmenko AP, Didenko GV, Shpak GE, Potebnya GP. Comparative evaluation of the antitumor efficacy of allogeneic and xenogeneic vaccine modified by protein metabolites of B. subtilis B-7025. Clin Oncol 2014; 4 (16): 90–4. (in Ukrainian).
Potebnya GP, Didenko GV, Kuzmenko OP, et al. A method of producing antitumor vaccine (Pat №77647 UA). Publ 16.07.2012. Bul №4. (in Ukrainian).
Kozhemyakin YuM, Kchromov OS, Filonenko MA, et al. Guideline on management of laboratory animals and work with them. K: Avicenna, 2002; 156 p. (in Ukrainian).
Ras M, Girbal-Neuhauser E, Paul E, Lefebvre D. A high yield multi-method extraction protocol for protein quantification in activated sludge. Bioresour Technol 2008; 99 (16): 7464–71. doi: 10.1016/j.biortech.2008.02.025.
Didenko GV, Sorokina LV, Shpak EuG, et al. The application of fullerene C60 for the modification of an anticancer vaccine based on metabolism products of Bacillus subtilis 7025. J Biol Phys Chem 2011; 11: 30–5.
Ohno M, Abe T. Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J Immunol Methods 1991; 145 (1–2): 199–203. doi: 10.1016/0022–1759(91)90327-c
Kristensen E, Reimann R. Direct cytotoxicity test applied to patients in stage I and II of malignant skin melanoma. Cancer Immunol Immunother 1977; 2: 49–55.
Goncharov AH, Frejdlin ES, Cmirnov VS, et al. Basics of clinical immunology and methodological approach to immune status evaluation: manuals. Kaliningrad: Kaliningrad Univ, 1997: 51. (in Russian)
Luo Y, Wen YJ, Ding ZhY, et al. Іmmunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res 2006; 12 (6): 1813–9. doi: 10.1158/1078–0432.CCR-05–1990
Biava PM, Fiorito A, Negro C, Mariani M. Effect of treatment with embryonic and uterine tissue homogenates on Lewis lung carcinoma development. Cancer Lett 1988; 41 (3): 265–70. doi: 10.1016/0304–3835(88)90287-x
Symchych TV, Fedosova NI, Karaman OM, et al. Cancer xenogeneic vaccines based on chicken antigens. Why not? Oncology 2021; 23 (1–2): 11–7. doi: 10.32471/oncology.2663–7928.t-23–1-2021-g.9368
Zatula DG. Experimental and clinical results of application of antitumor vaccines obtained by means of bacterial metabolism. Neoplasma1984; 31 (1): 65–74.
Didenko GV. The designing of antitumor vaccines on the basis of protein-containing metabolites of B. subtilis В-7025 and their effects on the separate reactions of anti-tumor immunity (experimental study). Kyiv, 2008. 19 p. (in Ukrainian).
Potebnya G, Cheremshenko N, Lisovenko G, et al. Antitumor efficacy of autovaccines prepared from chemoresistant tumor cells with the use of lectin of B. subtilis B-7025. Exp Oncol 2007; 4 (29): 277–80.
